NeOnc Technologies Holdings, Inc. (NTHI)
| Market Cap | 123.29M -13.2% |
| Revenue (ttm) | 39,990 +100.0% |
| Net Income | -47.20M |
| EPS | -2.14 |
| Shares Out | 24.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 151,304 |
| Open | 4.710 |
| Previous Close | 4.730 |
| Day's Range | 4.710 - 5.100 |
| 52-Week Range | 3.005 - 12.990 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 16.00 (+222.58%) |
| Earnings Date | Aug 10, 2026 |
About NTHI
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary bra... [Read more]
Financial Performance
In 2025, NTHI's revenue was $39,990, a decrease of -51.82% compared to the previous year's $83,000. Losses were -$62.15 million, 422.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NTHI stock is "Strong Buy." The 12-month stock price target is $16.0, which is an increase of 222.58% from the latest price.
News
NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger
DENVER, Aug. 28, 2026 (GLOBE NEWSWIRE) -- For NeOnc Technologies Holdings (NASDAQ: NTHI), the most important part of the NEO100 story may no longer be whether the company can produce a meaningful sign...
NeOnc's Clinical Story Is Now the Main Event
DENVER, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has reached a point where the market conversation can move toward a much more consequential question: What happens ...
NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't
DENVER, Aug. 18, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has just added another potentially important element to an already potent story: its CEO, Am...
These Nasdaq Stories Are Heating Up
DENVER, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Here are today's catalysts reshaping the market narrative. NeOnc Technologies Holdings: Phase 2a Data Could Just Be the Beginning NeOnc (NASDAQ: NTHI) has pro...
NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
NeOnc's (NASDAQ:NTHI) Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma make its Nasdaq Global Market listing way more interesting
NeOnc says Phase 2a portion of NEO100-01 study met primary endpoint
NeOnc Technologies (NTHI) announced topline results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV…
NeOnc Technologies Holdings Transcript: AGM 2026
The meeting confirmed a quorum and approved all proposals, including director elections, an equity incentive plan amendment, and auditor ratification. No shareholder questions were received, and the meeting concluded with plans to file final voting results.
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26
Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI).
The Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotech
DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings' (NASDAQ: NTHI) August 12 headline was impossible to miss, but another interesting solution may be hiding in plain sight: while Ne...
Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer
DALLAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has delivered the kind of clinical update that can change the conversation around a small biotechnology company: it...
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
Phase 2a results showed 48.9% six-month progression-free survival versus a 20% historical benchmark, with median overall survival reaching approximately 26 months Houston, Texas--(Newsfile Corp. - Aug...
NeOnc Technologies Holdings Transcript: Study result
NEO100, delivered intranasally, showed a median overall survival of 26.09 months in recurrent IDH1 mutant high-grade glioma, far exceeding the historical six to nine months. The phase II-A trial met its primary endpoint with a PFS6 of 48.9%, and demonstrated durable disease control and favorable tolerability.
NeOnc Technologies Holdings Press release: Study result
NeOnc Technologies Holdings issued a press release on August 12, 2026, disclosing material business information to investors.
NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
Company to request a Type B meeting with the FDA to align on a registrational path in a setting with no approved targeted therapy — Study met its primary endpoint: six-month progression-free survival ...
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence
Houston, Texas--(Newsfile Corp. - August 11, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is set up for a potential high impact catalyst day with what market observers are describing as a classi...
NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
NeOnc (Nasdaq: NTHI) will host an investor conference call and webcast on Wednesday, August 12, 2026, at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
NeOnc Technologies Holdings Quarterly report: Q2 2026
NeOnc Technologies Holdings has published its Q2 2026 quarterly earnings report on August 10, 2026.
NeOnc Technologies Holdings Earnings release: Q2 2026
NeOnc Technologies Holdings released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
CALABASAS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing no...
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a clinical-stage life sciences company focused on the development of t...
Wall Street is Watching These Biotechs
Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDAQ: ELAB) are pursuing a distinct therapeutic strategy
NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum
DENVER, June 24, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is entering one of the most significant periods in its corporate history after securing it...
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S. development, where ...
NeOnc Technologies Holdings Proxy statement: Proxy filing
NeOnc Technologies Holdings filed a proxy statement on June 23, 2026, providing details for shareholder voting and corporate governance matters.